Abstract
Using a similar strategy that was used to identify PR1 as a leukemia-associated antigen (LAA), we identified two homologous HLA-A2-restricted peptides from cyclin E1 (CCNE1M) and cyclin E2 (CCNE2L) that could be used to elicit peptide-specific CTL from healthy donors. The two peptides differ by a single amino acid at position 7 and have equal binding affinity for HLA-A2, and each elicited peptide-specific CTL with equal efficiency. Because each CCNE1M- and CCNE2L-CTL clone, derived from limiting dilution, cross-recognized the other homologous peptide, we hypothesized that each clone would efficiently kill leukemia that over-expressed either or both CCNE1 and CCNE2 proteins.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
